KYMR Q4 2021 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+19.5% YoY

Gross Profit

$15M100.0% margin

Operating Income

-$34M-222.5% margin

Net Income

-$34M-221.9% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

-24.9%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$39M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$606M

Total Liabilities

$146M

Stockholders' Equity

$460M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$13M	+19.5%
Gross Profit	$15M	$13M	+19.5%
Operating Income	-$34M	-$13M	-166.0%
Net Income	-$34M	-$13M	-167.3%